Early Closure of Temporary Loop Ileostomy After Rectal Resection for Cancer
Launched by ODENSE UNIVERSITY HOSPITAL · May 26, 2013
Trial Information
Current as of July 25, 2025
Unknown status
Keywords
ClinConnect Summary
The aim of this prospective randomized study is to compare early vs. late closer of the protecting ileostoma in patients requiring rectal resection for rectal cancer.
Early closer is defined as postoperative days 8-12 and delayed as later then 3 months.
Inclusion criteria is aged 18 years or older with rectal carcinoma, requiring rectal resection with a protecting ileostoma.
A CT-water-soluble contrast enema examination per rectum is performed at day 7, to evaluate the anastomosis in all patients. The patients will be randomized after the "intention-to-treat" principle, before the primar...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients aged 18 years or older.
- • All patients with rectal carcinoma, requiring elective rectal resection with primary anastomosis and an protecting ileostoma
- • Written informed consent was obtained from all patients
- Exclusion Criteria:
About Odense University Hospital
Odense University Hospital is a leading academic medical center located in Denmark, dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital is committed to enhancing patient outcomes and fostering collaboration among multidisciplinary teams. With a focus on translating scientific discoveries into practical applications, Odense University Hospital leverages its state-of-the-art facilities and expertise to conduct rigorous trials across various medical fields, ensuring adherence to the highest ethical and regulatory standards. Through these efforts, the hospital aims to contribute significantly to the global body of medical knowledge and improve the quality of care for patients both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Odense, Fyn, Denmark
Patients applied
Trial Officials
Mark Ellebæk, MD
Principal Investigator
Odense Universityhospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials